Biogen Idec Australia Pty Ltd

7 PBAC submissions on file, active 2005–2014. 43% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Fampridine
  Neurology · Not recommended · 2014—
• Natalizumab
  Neurology · Recommended · 2025other sponsor
• Alefacept
  Dermatology · Not recommended · 2005—
• Dimethyl fumarate
  Neurology · Recommended with restriction · 2019other sponsor
• Peginterferon beta-1a
  Neurology · Recommended with restriction · 2014—

Therapy area mix

Activity by year

2005 (1) · 2006 (1) · 2007 (1) · 2012 (1) · 2013 (1) · 2014 (2)

Rejection patterns

Across 4 Not recommended decisions on file.

• 1×insufficient evidence of clinically relevant absolute treatment effect
• 1×high placebo response rate (50.8% in placebo vs 55.4-57.0% in fampridine groups for 6-point MSWS-12 improvement) undermining responder identification
• 1×proposed PBS restriction would not adequately limit access to patients who truly respond
• 1×ENABLE study comparison inadequate (single-arm open-label
• 1×biased in favour of fampridine)